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Background
There have been conflicting reports on the efficacy of recombinant human activated 
protein C, or drotrecogin alfa (activated) (DrotAA), for the treatment of patients 
with septic shock.
Methods
In this randomized, double-blind, placebo-controlled, multicenter trial, we assigned 
1697 patients with infection, systemic inflammation, and shock who were receiving 
fluids and vasopressors above a threshold dose for 4 hours to receive either DrotAA 
(at a dose of 24 µg per kilogram of body weight per hour) or placebo for 96 hours. 
The primary outcome was death from any cause 28 days after randomization.
Results
At 28 days, 223 of 846 patients (26.4%) in the DrotAA group and 202 of 834 (24.2%) 
in the placebo group had died (relative risk in the DrotAA group, 1.09; 95% con-
fidence interval [CI], 0.92 to 1.28; P = 0.31). At 90 days, 287 of 842 patients (34.1%) 
in the DrotAA group and 269 of 822 (32.7%) in the placebo group had died (relative 
risk, 1.04; 95% CI, 0.90 to 1.19; P = 0.56). Among patients with severe protein C 
deficiency at baseline, 98 of 342 (28.7%) in the DrotAA group had died at 28 days, 
as compared with 102 of 331 (30.8%) in the placebo group (risk ratio, 0.93; 95% CI, 
0.74 to 1.17; P = 0.54). Similarly, rates of death at 28 and 90 days were not signifi-
cantly different in other predefined subgroups, including patients at increased risk 
for death. Serious bleeding during the treatment period occurred in 10 patients in 
the DrotAA group and 8 in the placebo group (P = 0.81).
Conclusions
DrotAA did not significantly reduce mortality at 28 or 90 days, as compared with 
placebo, in patients with septic shock. (Funded by Eli Lilly; PROWESS-SHOCK 
ClinicalTrials.gov number, NCT00604214.)
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R
ecombinant human activated pro-
tein C, or drotrecogin alfa (activated) 
(DrotAA), was approved for the treatment 
of severe sepsis in 2001 on the basis of the Pro-
spective Recombinant Human Activated Protein C 
Worldwide Evaluation in Severe Sepsis (PROWESS) 
study,1 a phase 3 international, randomized, con-
trolled trial that was stopped early for efficacy 
after the enrollment of 1690 patients with severe 
sepsis. Absolute mortality in the intention-to-
treat population was reduced by 6.1 percentage 
points, a relative risk reduction of 19.4%. Subse-
quent subgroup analysis suggested that the mor-
tality benefit was limited to patients with in-
creased illness severity (i.e., those with more than 
one sepsis-related dysfunctional organ or with 
an Acute Physiology and Chronic Health Evalua-
tion [APACHE] II score2 of more than 24 [on a 
scale of 0 to 71, with higher scores indicating an 
increased risk of death]). The Food and Drug Ad-
ministration limited its approval of the drug for 
use in patients with “a high risk of death” and 
requested additional trials involving less severely 
ill adults and children. These trials were termi-
nated early for futility by independent data and 
safety monitoring committees.3,4 Moreover, sub-
groups of patients at increased risk for death 
within the adult trial did not appear to benefit 
from the use of DrotAA. The lack of confirma-
tory data from placebo-controlled trials5 called 
into question the results of the PROWESS study 
and thus the efficacy of the drug.6
DrotAA received marketing authorization from 
the European Medicines Agency for the treatment 
of adults with severe sepsis and multiple organ 
failure, but the approval was subject to annual 
review.7 In 2007, the agency concluded that suf-
ficient doubt existed to warrant a new placebo-
controlled trial.8 We conducted the PROWESS-
SHOCK study to test the hypothesis that DrotAA, 
as compared with placebo, would reduce mortal-
ity in patients with septic shock.9
Methods
Study Patients
The study protocol has been published previously 
(www.springerlink.com/content/t3353213r20835ul/ 
fulltext.pdf).9 The trial was approved by the insti-
tutional review board at each study center, and 
written informed consent was obtained from pa-
tients or their legally authorized surrogates in 
accordance with local requirements.
Adult patients were eligible for inclusion if 
they had sepsis (infection and two or more signs 
of systemic inflammation), shock, and clinical 
evidence of hypoperfusion. We defined hypoperfu-
sion as metabolic acidosis (base deficit, ≥5.0 mmol 
per liter; venous bicarbonate, <18 mmol per liter; 
or lactate, >2.5 mmol per liter) or renal or he-
patic dysfunction. (Case definitions are provided 
in the protocol.) We defined shock as the need 
for treatment with norepinephrine at a dose of at 
least 5 µg per minute or an equivalent dose of 
another vasopressor for 4 hours or more, pro-
vided that at least 30 ml per kilogram of body 
weight of crystalloid or an equivalent volume of 
colloid was administered during the 8-hour inter-
val surrounding the start of vasopressor treatment. 
We required that patients remain refractory to 
reasonable attempts to wean vasopressors and 
begin study treatment within 24 hours after the 
first dose of a vasopressor. (Full details regard-
ing inclusion and exclusion criteria are provided 
in the Supplementary Appendix, available with the 
full text of this article at NEJM.org.)
Patients with coexisting illnesses with a high 
risk of death (e.g., metastatic cancer) were ex-
cluded. The clinical coordinating center con-
firmed the eligibility of each patient before ran-
domization.
Study Treatments
A centralized system randomly assigned patients 
to receive an intravenous infusion of DrotAA 
(Xigris, Eli Lilly) at a dose of 24 µg per kilogram 
of body weight per hour for 96 hours or match-
ing placebo dissolved in 0.9% saline solution. 
Study-group assignments were concealed from 
patients, investigators, treating clinicians, and 
the sponsor. Temporary interruptions of the study 
infusion were mandated for invasive procedures; 
in such cases, the infusion was extended through 
day 6 (the treatment period) so that the 96-hour 
infusion could be completed wherever possible. 
All other treatments were at the discretion of 
treating clinicians.
Evaluation of Patients
We assessed baseline demographic characteris-
tics, preexisting conditions, organ function, sites 
of infection, microbiology results, and hemato-
logic and laboratory measurements within 24 
hours before the administration of a study drug. 
Blood samples for the measurement of protein C 
levels were collected on days 1 through 7. Assays 
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to assess protein C activity were performed on an 
STA Compact coagulation analyzer with the use of 
the STA-Staclot protein C kit (Diagnostica Stago). 
Patients were followed until either 90 days or death.
Primary and Secondary Outcomes
The primary outcome was death at 28 days. Sec-
ondary outcomes included 28-day mortality in 
patients with severe protein C deficiency (plasma 
concentration, ≤50% of the lower limit of the nor-
mal range), 90-day mortality, measures of organ 
dysfunction, and safety. We examined hetero-
geneity of the treatment effect on mortality at 28 
and 90 days in prespecified subgroups, as de-
fined by the following baseline characteristics: 
APACHE II score (<25 or ≥25), number of organs 
that had failed, presence or absence of the acute 
respiratory distress syndrome (ARDS), the quar-
tile of time from the onset of shock to the initia-
tion of study treatment, plasma protein C level, 
glucocorticoid treatment, prophylactic heparin ad-
ministration, recent surgery, and platelet count.
We assessed organ function using Sequential 
Organ Failure Assessment (SOFA) scores (on a 
scale of 0 to 4 for each organ system, with higher 
scores indicating more severe organ dysfunction). 
We used the SOFA score to measure the change 
from baseline to study day 7, using the mean 
arterial pressure and vasopressor dose to measure 
cardiovascular function, the ratio of the partial 
pressure of oxygen in arterial blood to the frac-
tion of inspired oxygen to measure respiratory 
function, and the serum creatinine level to mea-
sure renal function.
Study Oversight
The steering committee designed the study in col-
laboration with the sponsor, Eli Lilly, as reported 
previously.9 Coauthors from the Duke Clinical 
Research Institute performed the analysis. The 
steering committee wrote the first draft of the 
manuscript, and the two first coauthors made 
the decision to submit the manuscript for publi-
cation. All authors had full and independent ac-
cess to all the data and vouch for the integrity, 
accuracy, and completeness of the analysis and 
its fidelity to the study protocol.10
Statistical Analysis
We determined that the planned enrollment of 
1500 patients would provide a power of 80% at 
a significance level of 0.05 to detect an absolute 
difference of 7 percentage points (20% relative 
risk reduction) in the primary outcome of 28-day 
mortality from the placebo rate of 35%. An inde-
pendent data and safety monitoring board con-
ducted interim analyses, as described previously.9 
The protocol specified an increase in sample size 
if the 28-day mortality for 750 patients was less 
than 30%.
The final primary analysis used a P value of 
less than 0.05 with adjustment for interim analy-
ses of the cumulative data. The 28-day primary 
efficacy analysis was conducted according to the 
intention-to-treat principle and documented in the 
statistical analysis plan, as described previous-
ly.9-11 Patients with unknown survival status at 
28 days or 90 days were excluded from the land-
mark analyses. In the time-to-event analyses, 
data for patients with unknown survival status 
were censored on the last day that patients were 
known to be alive.
We used a Cox proportional-hazards model to 
estimate the hazard ratio for death with the use 
of DrotAA versus placebo. We used a log-rank 
test to assess differences in survival curves be-
tween the two groups in the time-to-event 
analysis through 28 days and 90 days. Survival 
estimates were calculated with the use of the 
Kaplan–Meier method. We used the Wilcoxon 
rank-sum test to assess between-group differ-
ences in SOFA scores. Similarly, we used ranked 
analysis of variance to assess the change in pro-
tein C level from baseline to day 7 and to com-
pare the two study groups. We used the Bres-
low–Day test for homogeneity of odds ratios to 
determine differences in the treatment effect 
across categories for each of the prespecified 
subgroups at 28 days. All safety analyses were 
conducted in the population of treated patients.
Results
Study Patients
Aggregate mortality after recruitment of 750 pa-
tients was 27.6%. Therefore, we increased the 
sample size to 1696 on May 12, 2010. Patients 
were enrolled from March 2008 through August 
2011 at 208 sites in Europe, North and South 
America, Australia, New Zealand, and India (for 
details, see the Supplementary Appendix). From 
27,816 potential patients, we recruited 1697, with 
852 assigned to receive DrotAA and 845 assigned 
to receive placebo. We were able to evaluate the 
primary outcome in 1680 patients (99.0%) (Fig. 1).
A total of 71.7% of patients were recruited at 
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1697 Underwent randomization
27,816 Patients were assessed for eligibility
24,271 Did not meet inclusion criteria or met one
or more exclusion criteria
43 Were treated with open-label DrotAA
and were excluded
3545 Patients were referred to the clinical
coordinating center
1465 Were excluded
275 Were not expected to survive 28 days
194 Did not meet septic shock criteria
168 Had no evidence of infection
150 Had risk of bleeding
678 Had other reasons
2080 Were assessed for eligibility after review
383 Did not undergo randomization
252 Did not give consent
43 Had condition improve
17 Had condition worsen
3 Received open-label DrotAA
68 Had other reasons
852 Were assigned to receive DrotAA
833 (97.8%) Received DrotAA
18 Did not receive DrotAA
1 Had unknown reason or withheld consent
845 Were assigned to receive placebo
833 (98.6%) Received placebo
12 Did not receive placebo
6 Were excluded
2 Were lost to follow-up
4 Withdrew consent
11 Were excluded
4 Were lost to follow-up
7 Withdrew consent
846 Were included in the analysis at day 28 834 Were included in the analysis at day 28
4 Were excluded
4 Were lost to follow-up
12 Were excluded
6 Were lost to follow-up
6 Withdrew consent
842 Were included in the analysis at day 90 822 Were included in the analysis at day 90
Figure 1. Screening, Randomization, and Follow-up of the Study Patients.
Screening procedures for all sites were not standardized, and not all sites returned screening logs. To screen for eligi-
bility, sites were encouraged to identify all patients receiving vasopressors. If patients appeared to meet all inclusion 
and no exclusion criteria or if sites requested clarification, the clinical coordinating center was contacted. If the center 
confirmed eligibility, the site was authorized to randomly assign the patients. The reasons for exclusion are provided in 
Table S1 in the Supplementary Appendix. All patients who underwent randomization are included in the survival analy-
sis for 28 and 90 days; data for patients with unknown survival status (i.e., those who were lost to follow-up or with-
drew) were censored on the last day the patient was known to be alive. DrotAA denotes drotrecogin alfa (activated).
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European sites and 14.1% at North American 
sites, with 14.2% recruited from other countries. 
Baseline characteristics were similar in the two 
groups (Table S2 in the Supplementary Appendix): 
56.4% of the patients were men, and the mean 
(±SD) ages were 63.4±15.4 years in the DrotAA 
group versus 62.7±16.4 years in the placebo 
group. The mean APACHE II scores were 25.2±8.1 
and 25.5±8.1 in the DrotAA and placebo groups, 
respectively; 84.1% of the patients had dysfunc-
tion of three or more organs.
The site of infection, cultured organisms, and 
antimicrobial treatments were similar in the two 
groups (Table 1, and Table S3 in the Supplemen-
tary Appendix). The most common sites of infec-
tion were the lung, abdomen, and urinary tract. 
A causative pathogen was identified before start-
ing study treatment in 1198 of 1696 patients 
(70.6%); 509 of 1696 patients (30.0%) had posi-
tive blood cultures. The median time from the 
initiation of antibiotics to initial vasopressor 
therapy was 2.5 hours (interquartile range, 0 to 7.1) 
in the DrotAA group and 2.5 hours (interquartile 
range, 0 to 8.6) in the placebo group (P = 0.98). 
The control of infection at the presumed source 
was accomplished in 275 of 303 patients (90.8%) 
in the DrotAA group and 264 of 295 (89.5%) in 
the placebo group (P = 0.60).
Study Treatment and Cointerventions
Study treatment was administered to 1666 of 
1696 patients (98.2%) and was interrupted at 
least once in 593 of 1666 patients (35.6%). The 
mean total duration of study treatment was 
83.3±26.7 hours in the DrotAA group and 
85.1±25.1 hours in the placebo group. The major 
reason for interrupting a study treatment was an 
invasive procedure (in 215 of 306 patients with 
interruptions [70.3%] in the DrotAA group vs. 
238 of 287 [82.9%] in the placebo group). Study 
treatment was stopped prematurely in 216 of 833 
patients (25.9%) in the DrotAA group and 191 of 
833 (22.9%) in the placebo group. In the two 
groups, the most common reason for premature 
discontinuation was the patient’s death (Table S4 
in the Supplementary Appendix). The proportions 
of patients receiving glucocorticoids and anti-
coagulants were also similar in the two groups, 
Table 1. Site and Cause of Infection.*
Variable
Drotrecogin Alfa  
(Activated) Placebo
Primary site of infection — no./total no. (%)
Lung 369/851 (43.4) 375/845 (44.4)
Abdomen 263/851 (30.9) 246/845 (29.1)
Urinary tract 97/851 (11.4) 112/845 (13.3)
Skin 48/851 (5.6) 45/845 (5.3)
Other site† 74/851 (8.7) 67/845 (7.9)
Positive blood culture — no./total no. (%) 270/851 (31.7) 239/845 (28.3)
Community-acquired infection — no./total no. (%) 654/850 (76.9) 654/845 (77.4)
Identification of infectious organism — no./total no. (%) 623/851 (73.2) 575/845 (68.0)‡
Sensitivity of infectious organism to administered antibiotics —  
no./total no. (%)§
514/611 (84.1) 481/571 (84.2)
Time from initiation of antibiotics to initiation of vasopressor — hr
Median 2.5 2.5
Interquartile range 0–7.1 0–8.6
Source control of infection — no./total no. (%)¶ 275/303 (90.8) 264/295 (89.5)
* There was no significant difference between the two study groups, except as indicated.
† Other sites included the central nervous system, blood, heart, pleura, reproductive tract, bone, and head.
‡ P = 0.02
§ Drugs in this category are all antimicrobial agents that were administered before infusion of a study drug.
¶ Included in this category are patients who were treated for source control of infection (e.g., surgery, drainage, or removal 
of an infected central venous catheter) in the subgroup of patients for whom source control was deemed to be neces-
sary. The type and frequency of organisms recovered from blood are provided in Table S3 in the Supplementary Appendix.
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as were the number and site of surgical proce-
dures performed during the treatment period 
(Table S4 in the Supplementary Appendix).
Outcomes
The status of patients at 28 days is provided in 
Table S5 in the Supplementary Appendix. At 28 
days, 223 of 846 patients (26.4%) in the DrotAA 
group and 202 of 834 (24.2%) in the placebo 
group had died (relative risk in the DrotAA group, 
1.09; 95% confidence interval [CI], 0.92 to 1.28; 
P = 0.31). At 90 days, 287 of 842 patients (34.1%) 
in the DrotAA group and 269 of 822 (32.7%) in 
the placebo group had died (relative risk, 1.04; 
95% CI, 0.90 to 1.19; P = 0.56) (Table 2). In addi-
tion, the time-to-event analysis at 90 days showed 
similar results (hazard ratio, 1.07; 95% CI, 0.91 
to 1.26; P = 0.43 by the log-rank test) (Fig. 2A). 
There was no significant heterogeneity in the 
treatment effect on mortality at 28 days and 90 
days in the prespecified subgroups (Fig. 2B, and 
Fig. S1 in the Supplementary Appendix). Changes 
in organ function during the 7-day study period 
Table 2. Study Outcomes and Adverse Events.*
Outcome
Drotrecogin Alfa  
(Activated) Placebo
Relative Risk 
(95% CI) P Value
Death — no./total no. (%)
At 28 days 223/846 (26.4) 202/834 (24.2) 1.09 (0.92–1.28) 0.31
At 90 days 287/842 (34.1) 269/822 (32.7) 1.04 (0.90–1.19) 0.56
Change in SOFA score by day 7†
Cardiovascular −2.61±1.72 −2.69±1.70 0.44
Respiratory −0.71±1.23 −0.70±1.19 0.84
Renal −0.64±1.34 −0.64±1.34 0.99
Coagulation −0.03±1.18 −0.04±1.15 0.92
Liver −0.03±0.96 −0.03±0.91 0.63
At least one serious adverse event by day 28 — no./
total no. (%)‡
119/833 (14.3) 96/833 (11.5) 1.23 (0.96–1.59) 0.11
At least one bleeding event during treatment period 
— no./total no. (%)
Nonserious 72/833 (8.6) 40/833 (4.8) 1.80 (1.23–2.61) 0.002
Serious 10/833 (1.2) 8/833 (1.0) 1.25 (0.49–3.15) 0.81
Cerebral hematoma, cerebral or subarachnoid hem-
orrhage, or hemorrhagic stroke by day  
28 — no./total no. (%)
3/833 (0.4) 3/833 (0.4) 1.00 (0.20–4.90) 1.00
* Plus–minus values are means ±SD.
† Sequential Organ Failure Assessment (SOFA) scores range from 0 to 4 for each organ system, with higher scores indi-
cating more severe organ dysfunction. P values were calculated with the use of the Wilcoxon rank-sum test.
‡ A complete list of serious adverse events is provided in Table S6 in the Supplementary Appendix.
Figure 2 (facing page). Probability of Survival and Odds 
Ratios for Death, According to Subgroup.
Panel A shows Kaplan–Meier estimates for the proba-
bility of survival, which at 90 days did not differ signif-
icantly between patients receiving drotrecogin alfa 
 (activated) (DrotAA) and those receiving placebo (haz-
ard ratio, 1.07; 95% confidence interval, 0.91 to 1.26; 
P = 0.43 by the log-rank test). Panel B shows the odds 
ratios and 95% confidence intervals for death from any 
cause among all patients in the predefined subgroups. 
The size of the symbols indicates the relative number 
of deaths. Although the odds ratio for death at 28 days 
was a specified outcome in the predefined statistical 
analysis plan (Fig. S1 in the Supplementary Appendix), 
odds ratios at 90 days are shown because the outcome 
at 90 days was deemed to be more relevant to clini-
cians and patients. The Acute Physiology and Chronic 
Health Eval uation (APACHE) II score ranges from 0 to 
71 points, with higher scores indicating greater disease 
severity. Sequential Organ Failure Assessment (SOFA) 
scores range from 0 to 4 for each organ system, with 
higher scores indicating more severe organ dysfunction. 
Organ failure was defined as a SOFA score of 3 or 4 for 
any individual organ system. The protein C class indi-
cates the percentage of normal protein C activity. 
ARDS denotes acute respiratory distress syndrome.
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did not differ significantly in the two groups 
(Table 2). Protein C activity increased from base-
line during the first 6 days in both groups; the 
mean increase was significantly greater in pa-
tients in the DrotAA group than in the placebo 
group on each of the first 4 study days (P<0.001) 
(Fig. S2 in the Supplementary Appendix).
During the first 28 days, one or more serious 
adverse events were recorded in 119 of 833 pa-
tients (14.3%) in the DrotAA group versus 96 of 
833 patients (11.5%) in the placebo group (P = 0.10) 
(Table 2, and Table S4 in the Supplementary 
Appendix). During the treatment period, non-
serious bleeding events were more common 
among patients receiving DrotAA than among 
those receiving placebo (in 72 of 833 patients 
[8.6%] vs. 40 of 833 [4.8%], P = 0.002), as were seri-
ous bleeding events (in 10 of 833 patients [1.2%] 
vs. 8 of 833 [1.0%], P = 0.81), although the latter 
difference was not significant.
Discussion
In this large international study involving criti-
cally ill adults with septic shock, DrotAA did not 
reduce mortality at either 28 or 90 days, as com-
pared with placebo. The lack of benefit was con-
sistent across predefined subgroups.
The strengths of the trial lie in both its de-
sign and its execution. From the results of previ-
ous randomized trials, we identified a clinically 
relevant population of patients who were likely 
to benefit from treatment with DrotAA, and we 
predefined a limited number of relevant sub-
groups within this population.1,3,12-18 The char-
acteristics of the patients we recruited matched 
the population we targeted. The baseline charac-
teristics indicated a high degree of disease sever-
ity: 97.5% had multiple organ dysfunction, 90.2% 
had metabolic acidosis, and more than half had 
an elevated lactate level that persisted after fluid 
resuscitation. The baseline protein C level was 
markedly reduced in many patients. All patients 
remained dependent on vasopressors at study 
entry; most were treated with norepinephrine, 
with a median dose of 21 to 24 µg per minute 
at the start of study treatment. The baseline 
APACHE II score (which was designed to esti-
mate the risk of death among critically ill patients 
rather than to assess the eligibility of individual 
patients for particular treatments) was somewhat 
lower than expected. Similar APACHE II scores 
have been reported in a trial of treatments for 
septic shock,19 and such scores may reflect im-
proved early resuscitation, since they are sensi-
tive to lead-time bias.20,21
We used an adaptive design22 that allowed us 
to increase the sample size to maintain adequate 
statistical power, since some trials involving pa-
tients with severe sepsis showed lower-than-
expected mortality.19,23,24 To reduce the risk of 
assignment bias, we concealed study-group as-
signments before and after randomization, and 
to minimize crossovers, we used a standardized 
process to select hospitals and intensive care 
units that did not regularly treat patients with 
DrotAA. The success of these processes is evident 
in the excellent compliance with study treatment 
and the minimal crossover observed in the study. 
We achieved near complete follow-up and fol-
lowed a predefined, published statistical analy-
sis plan. We used mortality as an outcome that 
is less subject to biased ascertainment than other 
outcomes.25 We focused on mortality at 90 days,18 
since 45% of the patients were still hospitalized 
at 28 days, a percentage similar to that reported 
in the PROWESS study.
Our trial also has some limitations. We did not 
collect comprehensive data to study the coagula-
tion or inflammatory responses during infusion 
of the study drugs, although such data exist from 
previous trials.1,3,12,13,17,26 The between-group dif-
ference in protein C activity in our trial was 
similar to that seen in the PROWESS study,27,28 
and this finding combined with the expected 
increase in nonserious bleeding events in the 
DrotAA group5,13 indicates that the patients re-
ceived the intended treatment; both are indirect 
markers of the biologic activity of DrotAA. Mor-
tality in the placebo group was low, as compared 
with historical data,1,29-31 but consistent with 
that observed in more recent observational stud-
ies32,33 and trials.34,35
Our findings are consistent with results of the 
Administration of Drotrecogin Alfa (Activated) 
in Early Stage Severe Sepsis (ADDRESS) and the 
Resolution of Organ Failure in Pediatric Patients 
with Severe Sepsis (RESOLVE) trials, which 
showed that DrotAA did not reduce mortality in 
children or adults with severe sepsis who had a 
low risk of death.3,4 Our results are consistent 
with the finding in the ADDRESS trial in that 
DrotAA was not effective in patients with an 
increased disease severity.4 We cannot explain 
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the inconsistency between our findings and the 
reduction in mortality at 28 days that was ob-
served in the PROWESS study.1 Our findings of 
similar mortality at 90 days are consistent with 
those of the PROWESS study at 3 months, at 
which time mortality was not significantly re-
duced by DrotAA.36
Our study showed that DrotAA was not bene-
ficial when administered to a population of pa-
tients for which it was an approved treatment. 
The fact that we found no benefit in any of the 
prespecified subgroups should reassure clini-
cians who no longer have DrotAA available to 
treat patients with septic shock.37
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